POM-V Prescription Required Companion Animal

Marbocyl P 5 mg Tablet for Dogs and Cats

Active ingredient: Marbofloxacin

Form

Tablet

Species

Cats Dogs

Manufacturer

Vetoquinol UK Limited

VMD MA No.

08007/5024

What it's used for

In dogs Marbofloxacin is indicated in the treatment of:  furunculosis, cellulitis) caused by susceptible strains of organisms.  by susceptible strains of...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Marbofloxacin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Marbocyl P 5 mg Tablet for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

In dogs
Marbofloxacin is indicated in the treatment of:

furunculosis, cellulitis) caused by susceptible strains of organisms.

by susceptible strains of organisms.

In cats
Marbofloxacin is indicated in the treatment of skin and soft tissue
infections (wounds, abscesses, phlegmons) and upper respiratory tract
infections caused by susceptible strains of organisms.

Revised: July 2025
MA Split from NI MA Following AN:01098/2025Page 2 of 6

For oral administration.
The recommended dose rate is 2 mg/kg/d ( 1 tablet for 2.5 kg per day) in
single daily administration.
To ensure a correct dosage body weight should be determined as
accurately as possible to avoid underdosing.
DOGS:

Depending on the course of the disease, it may be extended up to
40 days.

Depending on the course of the disease, it may be extended up to
28 days.

Revised: July 2025
MA Split from NI MA Following AN:01098/2025Page 4 of 6

depending on the course of the disease, it may be extended up to
21 days.
CATS:

treatment duration is 3 to 5 days.


Marbofloxacin should not be used in dogs aged less than 12 months, or
less than 18 months for exceptionally large breeds of dogs, such as
Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth
period. Not recommended for use in cats aged less than 16 weeks.
Do not use in cases of hypersensitivity to fluoroquinolones or any of the
excipients of the product.
Do not use in cases of resistance against quinolones since (almost)
complete cross-resistance exists against other fluoroquinolones.
Not suitable for infections resulting from strict anaerobes, yeast or fungi.

At the therapeutic recommended dosage, no severe side-effects are to
be expected in dogs and cats. In particular, no lesions of the articular
joints were encountered in clinical studies at the recommended dose
rate. However, joint pain and/or neurological symptoms (ataxia,
aggression, convulsion, depression) may occur on rare occasions.
Allergic reactions have been observed (temporary skin reactions) due to
histamine release that may occur.
Mild side effects such as vomiting, softening of faeces, modification of
thirst or transient increase in activity may occasionally occur. These
signs cease spontaneously after treatment and do not necessitate
cessation of treatment.
The frequency of adverse reactions is defined using the following
convention:
- rare (more than 1 but less than 10 animals in 10,000 animals treated)

Nil

(i) Special precautions for use in animals
The fluoroquinolones have been shown to induce erosion of articular
cartilage in juvenile dogs and care should be taken to dose accurately
especially in young animals.
The fluoroquinolones are also known for their potential neurological side
effects. Cautious use is recommended in dogs and cats diagnosed as
suffering from epilepsy.
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin.
Fluoroquinolones should be reserved for the treatment of clinical
conditions which have responded poorly, or are expected to respond
poorly to other classes of antimicrobials. Whenever possible, use of
fluoroquinolones should be based on susceptibility testing. Use of the
product deviating from the instructions given in the SPC may increase
the prevalence of bacteria resistant to the fluoroquinolones and may
decrease the effectiveness of treatment with other quinolones due to the
potential for cross resistance.
(ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
People with known hypersensitivity to fluoroquinolones should avoid
using this product. In case of accidental ingestion seek medical attention
and show product label and/or package leaflet to the doctor. Wear
gloves when handling or dividing tablets. Wash hands after use.

Revised: July 2025
MA Split from NI MA Following AN:01098/2025Page 3 of 6

interaction
Fluoroquinolones are known to interact with orally administered cations
(Aluminium, Calcium, Magnesium, Iron). In such cases, the
bioavailability may be reduced.

No special precautions for storage

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.